Top Industry Leaders in the Benign Prostatic Hyperplasia Treatment Market
Latest Benign Prostatic Hyperplasia Treatment Companies Update:
Urotronic announces positive results from the PINNACLE clinical trial: The trial assessed the Optilume BPH System, a minimally invasive device combining mechanical dilation and paclitaxel delivery, showing significant improvements in urinary flow and symptom relief compared to sham procedure.
Teleflex expands its UroLift System reach to Japan: This FDA-approved system for BPH relief through tissue lifting utilizes tiny implants, offering a minimally invasive and effective alternative to traditional surgery.
Boston Scientific acquires NxThera, bolstering its BPH treatment portfolio: This acquisition brings NxThera's novel Prostatic Artery Embolization (PAE) technology for BPH treatment under Boston Scientific's umbrella, diversifying its offerings and catering to wider patient needs.
List of Benign Prostatic Hyperplasia Treatment Key companies in the market
- Air Liquide
- Abbott Laboratories
- AbbVie (Allergan Plc)
- Astellas Pharma Inc.
- Boehringer Ingelheim Pharma GmbH & Co. KG
- Eli Lilly and Company
- GlaxoSmithKline plc.
- Merck & Co., Inc. (Merck Sharp & Dohme Corp)
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Limited